Research article on "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates" in the Journal of Applied Health Economics and Health Policy (as of August 07, 2018).
Michael Schlander spoke on “The Value of a Statistical Life Year (VSLY) – An Analysis of Empirical Economic Studies from 1995 to 2015“ and “Attributes of Health Care Interventions that drive Social Willingness-To-Pay: Focus on Rarity (Insights from a Discrete Choice Experiment in Switzerland)” at the EuHEA Conference 2018 in Maastricht / The Netherlands, July 11 - 14, 2018.
Michael Schlander spoke on “Measuring Health-Related Quality of Life: German Patient Preferences for Generic Health States – Research based on the Multi-Instrument Comparison (MIC) Study“ at the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne / Germany, July 09, 2018.
Michael Schlander spoke on “Sustainability: Budgetary Impact and Cost Drivers for Rare and Ultra-Rare Diseases“ at a Workshop on “Health Systems Resilience for Rare Diseases” in Paris / France, June 27, 2018.
Michael Schlander presented “The Search for a Cost Effectiveness Standard: 1-3 Times GDP/Capita?“ and “Social Preferences for Health Care Interventions: The SoPHI Study” at the HTAi 2018 Annual Meeting in Vancouver / Canada, June 01 – 05, 2018.
Michael Schlander presented “New Estimates of the Willingness-To-Pay for a Statistical Life Year: A Systematic Review of the Empirical Economic Literature“ and “Should Rarity Matter? Results of a Social Willingness-To-Pay Study using the Discrete Choice Experiment (DCE) Method in Switzerland” at the ISPOR 2018 International Conference in Baltimore, MD / Untied States, May 19 – 23, 2018.
Michael Schlander was session chair and speaker on the subject "A Paradigm Shift in Value Frameworks for Access" as well as theme leader for "Economical Perspectives in Rare Diseases" at the 9th European Conference on Rare Diseases & Orphan Products (ECRD) in Vienna / Austria, May 10-12, 2018.
Michael Schlander spoke on "Social Willingness to Pay” and the case for “Social Cost Value Analysis” at the International Symposium on “Accessibility to High-Value Medicines" (London School of Hygiene & Tropical Medicine), in London / England, on December 6, 2017.
At the 20th European Congress of ISPOR in Glasgow, Scotland, Michael Schlander was interviewed by Cathy Jordan from GalbraithWight, answering questions on topical subjects and controversies in the field of health economics.